Attached files
| file | filename |
|---|---|
| EX-99.2 - EX-99.2 - Recro Pharma, Inc. | d288858dex992.htm |
| EX-99.1 - EX-99.1 - Recro Pharma, Inc. | d288858dex991.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8–K
CURRENT REPORT
Pursuant to Section 13 OR 15 (d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 28, 2016
Recro Pharma, Inc.
(Exact name of registrant as specified in its charter)
| Pennsylvania | 001-36329 | 26-1523233 | ||
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) | ||
| 490 Lapp Road, Malvern, Pennsylvania |
19355 | |||
| (Address of principal executive offices) | (Zip Code) | |||
Registrant’s telephone number, including area code: (484) 395-2470
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8–K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to Rule 14a–12 under the Exchange Act (17 CFR 240.14a–12) |
| ☐ | Pre–commencement communications pursuant to Rule 14d–2(b) under the Exchange Act (17 CFR 240.14d–2(b)) |
| ☐ | Pre–commencement communications pursuant to Rule 13e–4(c) under the Exchange Act (17 CFR 240.13e–4(c)) |
| Item 8.01 | Other Events. |
On November 28, 2016, Recro Pharma, Inc. (the “Company”) issued a press release announcing positive results from its second of two Phase III clinical trials evaluating intravenous meloxicam for the treatment of acute postoperative pain (the “Phase III Results”). A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
On November 28, 2016, the Company posted to its website slides reflecting the Phase III Results (the “Phase III Results Slides”), which will be incorporated into the Company’s investor presentation that was previously filed as Exhibit 99.1 to the Company’s Current Report on Form 8-K, dated November 15, 2016. A copy of the Phase III Results Slides are attached as Exhibit 99.2 to this Current Report on Form 8-K and are incorporated herein by reference. Representatives of the Company will use the investor presentation, including the Phase III Results Slides, in various meetings with investors from time to time.
| Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits
| Exhibit No. |
Document | |
| 99.1 | Press release of Recro Pharma, Inc., dated November 28, 2016. | |
| 99.2 | Phase III Results Slides. | |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: November 28, 2016
| Recro Pharma, Inc. | ||
| By: | /s/ Gerri A. Henwood | |
| Name: | Gerri A. Henwood | |
| Title: | Chief Executive Officer | |
EXHIBIT INDEX
| Exhibit No. |
Document | |
| 99.1 | Press release of Recro Pharma, Inc., dated November 28, 2016. | |
| 99.2 | Phase III Results Slides. | |